Chengdu Xinzhenghe Pharmaceutical Technology

Chengdu Xinzhenghe Pharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of next-generation RNA interference (RNAi) therapeutics. The company is a key entity within the Argo Biopharma (Shanghai Bowang) ecosystem, serving as a primary holder of intellectual property for a diverse pipeline of siRNA candidates. Its research focuses on targeting high-impact proteins such as Lipoprotein(a) (LPA) and Angiotensinogen (AGT) to treat cardiovascular and metabolic diseases. Leveraging advanced GalNAc-siRNA conjugation technology, Chengdu Xinzhenghe aims to provide potent and long-acting treatments for chronic conditions including hypertension and hypercholesterolemia. The company's portfolio includes several programs currently in clinical trials, positioning it as a significant player in the Chinese RNAi landscape.